H4 Orphan Pharma

We develop drugs
to cure patients with fibrotic diseases.

A breakthrough innovation

We are currently developing molecules that are multifunctional ligands, meaning that they act on several targets at the same time.

Intellectual property

We are the sole owners of our patents, which are registered and granted worldwide.

A highly experienced team

We work with the best international experts to develop our medicines.

Optimising resources

We invest 83% of our financial resources in R&D.

Carbon footprint

Our carbon footprint is reduced to an absolute minimum.

Discover H4 Orphan Pharma

H4 Orphan Pharma is a French pharmaceutical company founded in 2016 that is revolutionising the therapeutic approach
to fibrotic diseases

H4 Orphan Pharma is developing two drug candidates with strong global commercial potential targeting orphan diseases: idiopathic pulmonary fibrosis and dry eye, in particular Gougerot-Sjögren’s syndrome.

Drug candidates
Patent families
+ 0
Patents granted